Our most recent episode of The Expert Series podcast explores the newly released SLE treatment guidelines and how they might affect patient care.

The Lupus Research Alliance applauds the decision by the U.S. Food and Drug Administration (FDA) to grant Breakthrough Therapy designation for litifilimab (BIIB059) in clinical development by Biogen ...

There are a few to keep in mind.

Designation is based on the breadth of available litifilimab data, including the Phase 2 LILAC study result that showed improvements in cutaneous ...

An international team, led by Paul R. Fortin of Université Laval, has just identified three markers that would allow for establishing, right at the time of diagnosis, the risk of a lupus ...

The FDA has granted breakthrough therapy designation for litifilimab in patients with cutaneous lupus erythematosus, according to a press release from manufacturer Biogen. Litifilimab (Biogen) is a ...

The striking benefits achieved with emerging treatment options for recalcitrant connective tissue diseases offer the ...

Today, the Lupus Research Alliance, the world's largest private funder of lupus research, announced the 2025 Global Team ...

Kyleigh MacGregor plans her life five years at a time. MacGregor has lupus, an incurable disease in which her immune system attacks her body’s organs and tissue. It’s been a year since MacGregor, 31, ...

Eventual tapering and withdrawal of steroids in patients with lupus nephritis is recommended to minimize the drugs' adverse effects, but the ideal timing is uncertain. This study followed 136 lupus ...

A doctor advising ... sleepaway camp? That’s how a 12-year-old diagnosed with lupus found himself laughing on a high-ropes course as fellow campers hoisted him into the air. “It’s really fun,” said ...